InsidersTradesSigma
Follow the Spark Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was disclosed on 4 January 2016 (Cession). Among the most active insiders: Children's Hospital of Philadelphia Foundation. Every trade is free.
Analysts rate Spark Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
Spark Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. It is listed on the NASDAQ under the ticker ONCE.